Threshold Pharma (THLD) -24.2% premarket after disclosing its recent Phase 2b clinical trial of...

|About: Threshold Pharmaceuticals, ... (THLD)|By:, SA News Editor

Threshold Pharma (THLD) -24.2% premarket after disclosing its recent Phase 2b clinical trial of the investigational hypoxia-targeted drug TH-302 in combination with Gemcitabine boosted the survival of pancreatic patients but only by 4.5% - not enough to be statistically significant.